Macular degeneration is the leading cause of vision loss in older adults, but scientists have long struggled to study and replicate key elements of the disease in the lab.
You are here
Coverage of the latest news and updates from the field of stem cells.
While Zika virus causes devastating damage to the brains of developing fetuses, it one day may be an effective treatment for glioblastoma, a deadly form of brain cancer. New research from Washington University School of Medicine in St.
Longeveron LLC, a regenerative medicine company developing cellular therapies, has treated its first patient in a Phase 2b clinical trial evaluating the safety and efficacy of its human allogeneic mesenchymal stem cells (LMSCs) in patients with aging frailty syndrome. Aging frailty is a comm
Scientists working to develop new treatments for neurodegenerative diseases have been stymied by the inability to grow human motor neurons in the lab.
Scientists at Children's Hospital of Philadelphia (CHOP) report that a drug candidate that blocks abnormal protein signals may lead to the first pharmacologic treatment for hereditary multiple exostoses (HME), a rare pediatric genetic disease.
The U.S. Food and Drug Administration took what it called “decisive action to prevent the use of a potentially dangerous and unproven treatment” belonging to StemImmune Inc.
Japanese researchers report promising results from an experimental therapy for Parkinson’s disease that involves implanting neurons made from reprogrammed stem cells into the brain.
A new study in mice, conducted by researchers at the University of California, Irvine, details a potential therapeutic strategy that uses stem cells to promote recovery of motor activity after spinal cord injury.
The first subject has been transplanted in an investigator-initiated study of Cordin™ for patients with severe aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS) who have no available matched donor.
ViraCyte LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, reported positive data from a Phase 2 clinical trial evaluating its T-cell immunotherapy product, Viralym-M.